| Title | Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting / |
|---|---|
| Authors | Modvig, S ; Hallböök, H ; Madsen, H O ; Siitonen, S ; Rosthøj, S ; Tierens, A ; Juvonen, V ; Osnes, L T N ; Vålerhaugen, H ; Hultdin, M ; Matuzevičienė, Rėda ; Stoškus, M ; Marincevic, M ; Lilleorg, A ; Ehinger, M ; Norén-Nystrøm, U ; Toft, N ; Taskinen, M ; Jónsson, O G ; Pruunsild, K ; Vaitkevičienė, Goda Elizabeta ; Vettenranta, K ; Lund, B ; Abrahamsson, J ; Porwit, A ; Schmiegelow, K ; Marquart, H V |
| DOI | 10.1038/s41375-020-01100-5 |
| Full Text |
|
| Is Part of | Leukemia.. London : Springer Nature. 2021, vol. 35, iss. 7, p. 1894-1906.. ISSN 0887-6924. eISSN 1476-5551 |
| Abstract [eng] | PCR of TCR/Ig gene rearrangements is considered the method of choice for minimal residual disease (MRD) quantification in BCP-ALL, but flow cytometry analysis of leukemia-associated immunophenotypes (FCM-MRD) is faster and biologically more informative. FCM-MRD performed in 18 laboratories across seven countries was used for risk stratification of 1487 patients with BCP-ALL enrolled in the NOPHO ALL2008 protocol. When no informative FCM-marker was available, risk stratification was based on real-time quantitative PCR. An informative FCM-marker was found in 96.2% and only two patients (0.14%) had non-informative FCM and non-informative PCR-markers. The overall 5-year event-free survival was 86.1% with a cumulative incidence of relapse (CIR5y) of 9.5%. FCM-MRD levels on days 15 (HzR 4.0, p 10-4 associated with a CIR5y = 22.1%. In conclusion, FCM-MRD performed in a multicenter setting is a clinically useful method for MRD-based treatment stratification in BCP-ALL. |
| Published | London : Springer Nature |
| Type | Journal article |
| Language | English |
| Publication date | 2021 |
| CC license |
|